HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gibson S Kibiki Selected Research

Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)

4/2023Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
1/2023Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
2/2019Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gibson S Kibiki Research Topics

Disease

16Tuberculosis (Tuberculoses)
01/2023 - 06/2007
5Pulmonary Tuberculosis
10/2021 - 04/2007
5Infections
01/2019 - 08/2011
3Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
04/2023 - 02/2019
3Acquired Immunodeficiency Syndrome (AIDS)
02/2015 - 09/2011
2Opportunistic Infections (Opportunistic Infection)
02/2015 - 11/2011
1Drug-Related Side Effects and Adverse Reactions
04/2023
1Body Weight (Weight, Body)
10/2019
1Communicable Diseases (Infectious Diseases)
02/2019
1Bacterial Infections (Bacterial Infection)
01/2019
1Hearing Loss (Hearing Impairment)
01/2018
1Bacterial Meningitis
01/2018
1Cognitive Dysfunction
01/2018
1Prediabetic State (Prediabetes)
04/2016
1Gastritis
01/2014
1Coinfection
11/2011
1Rupture
10/2011
1Pre-Eclampsia (Preeclampsia)
10/2011
1Respiratory Tract Infections (Respiratory Tract Infection)
08/2011
1Lung Diseases (Lung Disease)
04/2007
1Hypersensitivity (Allergy)
04/2007

Drug/Important Bio-Agent (IBA)

9Rifampin (Rifampicin)FDA LinkGeneric
01/2023 - 08/2011
5PyrazinamideFDA LinkGeneric
01/2023 - 09/2013
5Isoniazid (Ftivazide)FDA LinkGeneric
10/2019 - 08/2011
4FluoroquinolonesIBA
01/2023 - 01/2010
3Ethambutol (Myambutol)FDA LinkGeneric
10/2019 - 09/2013
2Biomarkers (Surrogate Marker)IBA
10/2021 - 10/2019
2Moxifloxacin (Avelox)FDA Link
01/2017 - 08/2011
2AcidsIBA
02/2014 - 10/2007
2Emtricitabine (Emtriva)FDA Link
01/2013 - 11/2011
2efavirenz (Sustiva)FDA Link
01/2013 - 11/2011
2Tenofovir (Viread)FDA Link
01/2013 - 11/2011
1Acetylcysteine (Siran)FDA LinkGeneric
04/2023
1Clofazimine (Lamprene)FDA Link
01/2023
1thiamine triphosphorate (TTP)IBA
10/2019
1Ceftriaxone (Ceftriaxon)FDA LinkGeneric
01/2019
1Anti-Bacterial Agents (Antibiotics)IBA
01/2018
1Coloring Agents (Dyes)IBA
01/2018
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
04/2016
1Capreomycin (Capastat)FDA Link
09/2013
1Ethionamide (Trecator-SC)FDA Link
09/2013
1KanamycinFDA Link
09/2013
1Amikacin (A.M.K)FDA LinkGeneric
09/2013
1DNA (Deoxyribonucleic Acid)IBA
09/2013
1TabletsIBA
01/2013
1AerosolsIBA
07/2012
1Fluconazole (Zonal)FDA LinkGeneric
01/2012
1Ciprofloxacin (Cipro)FDA LinkGeneric
08/2011
1Toll-Like Receptor 4IBA
06/2007
1Macrophage Migration-Inhibitory FactorsIBA
04/2007

Therapy/Procedure

4Therapeutics
02/2015 - 11/2011
3Duration of Therapy
01/2018 - 01/2010
1Retreatment
04/2016
1Cesarean Section (Caesarean Section)
10/2011
1Micro-Electrical-Mechanical Systems
09/2011